IMRX
Immuneering Corporation
There isn't enough reported data to score IMRX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
IMRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
IMRX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
IMRX PE Valuation
IMRX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
IMRX Forward outlook
There aren't enough analyst estimates for IMRX to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
IMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.14 | +$0.65 |
| Q2 2026 | -$1.15 | +$0.75 |
| Q1 2026 | -$1.28 | +$0.69 |
| Q4 2025 | -$1.49 | +$0.55 |
| Q3 2025 | -$1.79 | +$0.17 |
| Q2 2025 | -$1.90 | $0.00 |
| Q1 2025 | -$1.97 | -$0.11 |
| Q4 2024 | -$2.04 | -$0.16 |
IMRX is still losing money, but far less than before: $1.14 per share over the past year, against $2.97 at its worst in late 2021.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over IMRX on earnings quality, reporting a profit while its opponent remains loss making.
IMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $455 | -100% |
| Q3 2022 | $38.4K | -92% |
| Q2 2022 | $94.4K | -86% |
| Q1 2022 | $183.7K | -75% |
| Q4 2021 | $189.6K | -71% |
| Q3 2021 | $482.1K | -29% |
| Q2 2021 | $660K | +37% |
| Q1 2021 | $748.2K | +55% |
UNH has the stronger quarterly revenue trend. Revenue is down 100% for IMRX versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -3073628% | -3067765 points |
| Q3 2022 | -34362% | -32590 points |
| Q2 2022 | -12334% | -11124 points |
| Q1 2022 | -7036% | -6203 points |
| Q4 2021 | -5863% | -4986 points |
| Q3 2021 | -1772% | -1127 points |
| Q2 2021 | -1211% | -461 points |
| Q1 2021 | -833% | -163 points |
IMRX's operating margin was −3073628% last quarter, down 3067765 points from the same quarter a year ago, near the bottom of its range since 2020.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
IMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.8M | -$4.8M |
| Q2 2026 | -$16.5M | -$7.1M |
| Q1 2026 | -$18.5M | -$4.4M |
| Q4 2025 | -$10M | +$4.6M |
| Q3 2025 | -$12M | +$1.5M |
| Q2 2025 | -$9.4M | +$2.1M |
| Q1 2025 | -$14.1M | +$1.4M |
| Q4 2024 | -$14.5M | -$2.6M |
IMRX has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over IMRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +17K shares |
| 1 year | +63% | +25M shares |
| 3 years | +121% | +35.4M shares |
| 5 years | +1206% | +59.8M shares |
| Available history | +379% | +51.2M shares |
IMRX has 65M diluted shares, up 63% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over IMRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
IMRX Net Leverage
IMRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
IMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 16.4 | Oversold |
IMRX's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
IMRX PE vs Healthcare Sector
IMRX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
IMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.84 | 4.4% below |
| 20 week MA | $4.38 | 16% below |
| 50 week MA | $4.91 | 25% below |
| 100 week MA | $4.24 | 13% below |
| 200 week MA | $4.78 | 23% below |
IMRX is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over IMRX on trend strength, trading above more of its moving averages.
IMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.6 | $20.5 | +17% |
| 2022 | $20.5 | $4.37 | -79% |
| 2023 | $4.37 | $7.35 | +68% |
| 2024 | $7.35 | $2.33 | -68% |
| 2025 | $2.33 | $6.73 | +189% |
| 2026 YTD | $6.73 | $3.67 | -45% |
IMRX's yearly returns have swung widely, from +189% in 2025 to −79% in 2022. It's down 45% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over IMRX on returns for 2026, with the stronger performance.